---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-059289"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T14:56:49.957973+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kyverna Therapeutics appoints Marc Grasso as CFO; Ryan Jones moves to advisor

## Summary
- Dr. Marc Grasso appointed CFO effective June 30, 2025; previously CFO of Alector (ALEC) and Kura Oncology (KURA).
- Outgoing CFO Ryan Jones will serve as strategic advisor through August 8, 2025; receives severance including 9 months salary and continued vesting.
- Grasso receives base salary of $510,000, sign-on bonus of $250,000, and option for 450,000 shares vesting over four years.
- Grasso brings over 25 years of experience in public company finance and biotech investment banking.

## SEC filing metadata
- accession: 0001213900-25-059289
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000121390025059289/0001213900-25-059289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000121390025059289/ea0247451-8k_kyverna.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-059289
- JSON: https://secwatch.observer/filing/0001213900-25-059289.json
- Plain text: https://secwatch.observer/filing/0001213900-25-059289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.